Product Description
Goserelin is a type of hormone therapy called luteinising hormone blocker. This means it stops the release of luteinising hormone (LH) from the pituitary gland. Goserelin is a treatment for people who have oestrogen receptor positive (ER positive) breast cancer. This means that the cancer has proteins (receptors) for the hormone oestrogen. (Sourced from: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/goserelin-breast-cancer)
Mechanisms of Action: GnRH Agonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Endometriosis | Breast Cancer | Endometrial Cancer | Prostate Cancer | Uterine Cancer | Oncology Unspecified | Injuries/wounds Unspecified
Known Adverse Events: Depressive Disorder | Headache | Breast Cancer | Uterine Cancer | Oncology Unspecified | Vaginitis | Edema | Hot Flashes | Lower Urinary Tract Symptoms | Injuries/wounds Unspecified
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czech Republic, Denmark, Egypt, Estonia, Finland, France, Georgia, Germany, Hong Kong, Hungary, India, Italy, Japan, Jordan, Korea, Lebanon, Malaysia, Mexico, Netherlands, Poland, Portugal, Russia, Saudi Arabia, Singapore, South Africa, Spain, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Unknown Location, Vietnam
Active Clinical Trial Count: 24
Highest Development Phases
Phase 3: Adenocarcinoma|Bone Cancer|Breast Cancer|Endometriosis|Male Breast Cancer|Prostate Cancer
Phase 2: Lobular Carcinoma|Triple Negative Breast Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
PREDICT-RT* | P3 |
Recruiting |
Prostate Cancer|Bone Cancer|Adenocarcinoma |
2033-12-31 |
|
S65935 | P3 |
Unknown Status |
Prostate Cancer |
2032-06-01 |
|
GUIDANCE | P3 |
Recruiting |
Prostate Cancer|Adenocarcinoma |
2032-04-30 |
|
ESCALATE | P2 |
Not yet recruiting |
Triple Negative Breast Cancer |
2026-12-01 |